US Patent

US10973806 — Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin

Method of Use · Assigned to Abraxis Bioscience LLC · Expires 2036-06-29 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating epithelioid cell tumors by administering a composition of nanoparticles containing an mTOR inhibitor and albumin.

USPTO Abstract

The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.

Drugs covered by this patent

Rapamune (sirolimus) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3258`	—	Rapamune

Patent Metadata

Patent number: US10973806
Jurisdiction: US
Classification: Method of Use
Expires: 2036-06-29
Drug substance claim: No
Drug product claim: No
Assignee: Abraxis Bioscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.